Gestational diabetes (GD), defined as carbohydrate intolerance with onset or first recognition during pregnancy, has a prevalence of 7% and is a growing problem worldwide. Infants born to mothers with GD are more likely to be large for gestational age, incur traumatic birth injury, require a stay in the intensive care unit and develop postnatal metabolic disturbances. As the worldwide epidemic of obesity worsens, more women are entering pregnancy with metabolic alterations and preexisting insulin resistance, which is heightened by the hormonal milieu of pregnancy. The Hyperglycemia Adverse Pregnancy Outcome (HAPO) study has clearly shown that GD-related complications correlate with glycemic control. We will review the current understanding of the physiology of GD and the screening and treatment guidelines that are commonly utilized in clinical care. In addition, we will discuss the need for development of multiparametric models combining maternal clinical risk factors and biomarkers early in pregnancy to better stratify and predict risk of GD-related complications and offer targeted intervention.

Keywords:
Gestational diabetes, Prediction, Screening
1.
Buchanan T, Xiang A: Gestational diabetes mellitus. J Clin Invest 2005;115:485-491.
2.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, et al: International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-682.
3.
Metzger BE, Buchanan TA, Coustan DR, et al: Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007;30(suppl 2):S251-S260.
4.
The HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, et al: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
5.
Wier L, Witt E, Burgess J, Elixhause A: Hospitalizations Related to Diabetes in Pregnancy, 2008: Statistical Brief No. 102. Rockville, Agency for Healthcare Policy and Research, 2010. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb102.pdf.
6.
Catalano PM, Tyzbir ED, Wolfe RR, et al: Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol 1993;264:60-67.
7.
Butte N: Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000;71(suppl 5):1256-1261.
8.
Issler JR: Diabetes Gestacional. Cuadros que corresponden a la principal causa de muerte materna. Revista de Posgrado de la VIa Cátedra de Medicina 2005;152:23-27.
9.
Yang X, Hsu-Hage B, Zhang H, Zhang C, Zhang Y, Zhang C: Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. Diabetes Care 2002;25:1619-1624.
10.
Saucedo R, Zarate A, Basurto L, Hernandez M, Puello E, Campos S, Moreno E: Women with gestational diabetes develop glucose intolerance with high frequency within one year postpartum. Gynecol Obstet Invest 2012;73:58-62.
11.
Vrachnis N, Augoulea A, Iliodromiti Z, Lambrinoudaki I, Sifakis S, Creatsas G: Previous gestational diabetes mellitus and markers of cardiovascular risk. Int J Endocrinol 2012;2012:458610.
12.
Mimouni F, Miodovnik M, Whitsett JA, Holroyde JC, Siddiqi TA, Tsang RC: Respiratory distress syndrome in infants of diabetic mothers in the 1980s: no direct adverse effect of maternal diabetes with modern management. Obstet Gynecol 1987;69:191-195.
13.
Hod M, Merlob P, Friedman S, Schoenfeld A, Ovadia J: Gestational diabetes mellitus. A survey of perinatal complications in the 1980s. Diabetes 1991;40(suppl 2):74-78.
14.
Silverman BL, Rizzo T, Green OC, Cho NH, Winter RJ, Ogata ES, Richards GE, Metzger BE: Long-term prospective evaluation of offspring of diabetic mothers. Diabetes 1991;40(suppl 2):121-125.
15.
Yajnik C: Fetal programming of diabetes: still so much to learn. Diabetes Care 2010;33:1146-1147.
16.
Knowler W, Pettitt DJ, Kunzelman CL, Everhart J: Genetic and environment determinants of non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1985;1:S309.
17.
Yessoufou A, Moutairou K: Maternal diabetes in pregnancy: early and long-term outcomes on the offspring and the concept of ‘metabolic memory'. Exp Diabetes Res 2011;2011:218598.
18.
Plagemann A, Harder T, Janert U, Rake A, Rittel F, Rohde W, Dörner G: Malformation of hypothalamic nuclei in hyperinsulinaemic offspring of gestational diabetic mother rats. Dev Neurosci 1999;21:58-67.
19.
Crume TL, Ogden L, Daniels S, et al: The impact of in utero exposure to diabetes on childhood body mass index growth trajectories: the EPOCH study. J Pediatr 2011;158:941-946.
20.
Landon MB, Spong CY, Thom E, et al: A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361:1339-1348.
21.
Morisset AS, Tchernof A, Dubé MC, et al: Weight gain measures in women with gestational diabetes mellitus. J Womens Health (Larchmt) 2011;20:375-380.
22.
Phaloprakarn C, Tangjitgamol S, Manusirivithaya S, et al: A risk score for selective screening for gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol 2009;145:71-75.
23.
National Institute for Health and Clinical Excellence: Diabetes in Pregnancy: Management of Diabetes and Its Complications from Pre-Conception to the Postnatal Period. NICE Clinical Guideline 63. London, NICE, 2008.
24.
Minsart A, Lescrainier J: Selective versus universal screening for gestational diabetes mellitus: an evaluation of Naylor's model. Gynecol Obstet Invest 2009;68:154-159.
25.
American College of Obstetricians and Gynecologists Committee on Practice Bulletins - Obstetrics: ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001;98:525-538.
26.
American Diabetes Association: Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(suppl 1):S11-S66.
27.
Leiva A, Pardo F, Ramírez M, Farías M, Casanello P, Sobrevia L: Fetoplacental vascular endothelial dysfunction as an early phenomenon in the programming of human adult diseases in subjects born from gestational diabetes mellitus or obesity in pregnancy. Exp Diabetes Res 2011;2011:349286.
28.
National Collaborating Centre for Women's and Children's Health: Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. London, RCOG Press, 2008.
29.
Plasencia W, García R, Pereira S, Akolekar R, Nicolaides K: Criteria for screening and diagnosis of gestational diabetes mellitus in the first trimester of pregnancy Fetal Diagn Ther 2011;30:108-115.
30.
Riskin-Mashiah S, Damti A, Younes G, et al: First trimester fasting hyperglycemia as a predictor for the development of gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol 2010;152:163-167.
31.
Bitó T, Földesi I, Nyári T, Pál A: Prediction of gestational diabetes mellitus in a high-risk group by insulin measurement in early pregnancy. Diabet Med 2005;22:1434-1439.
32.
Grewal E, Kansara S, Kachhawa G, et al: Prediction of gestational diabetes mellitus at 24 to 28 weeks of gestation by using first-trimester insulin sensitivity indices in Asian Indian subjects. Metabolism 2012;61:715-720.
33.
Laughon SK, Catov J, Provins T, et al: Elevated first-trimester uric acid concentrations are associated with the development of gestational diabetes. Am J Obstet Gynecol 2009;201:402.e1-e5.
34.
Georgiou H, Illanes S, Rice G, et al: Novel Screening Approaches for the Early Detection of Gestational Diabetes Mellitus; in Radenkovic M (ed): Gestational Diabetes. Rijeka, Croatia, In-Tech, 2011.
35.
Beneventi F, Simonetta M, Lovati E, et al: First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes. Prenat Diagn 2011;31:523-528.
36.
Caglar GS, Ozdemir ED, Cengiz SD, et al: Sex-hormone-binding globulin early in pregnancy for the prediction of severe gestational diabetes mellitus and related complications. J Obstet Gynaecol Res 2012;38:1286-1293.
37.
Wiznitzer A, Mayer A, Novack V, et al: Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 2009;201:482.e1-e8.
38.
Wolf M, Sandler L, Hsu K, et al: First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 2003;26:819-824.
39.
Ferreira A, Rezende J: Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem 2011;57:4.
40.
Agarwal M, Dhatt G: Gestational diabetes: an evaluation of serum fructosamine as a screening test in a high-risk population. Gynecol Obstet Invest 2011;71:207-212.
41.
Kim S, Park J, Norwitz E, Lee S, Kim B, Park C, Jun J, Kim C, Syn H: Identification of proteomic biomarkers in maternal plasma in the early second trimester that predict the subsequent development of gestational diabetes. Reprod Sci 2012;19:202-209.
42.
Georgiou HM, Lappas M, Georgiou GM, et al: Screening for biomarkers predictive of gestational diabetes mellitus. Acta Diabetologica 2008;45:157-165.
43.
Savvidou M, Nelson SM, Makgoba M, et al: First-trimester prediction of gestational diabetes mellitus: examining the potential of combining maternal characteristics and laboratory measures. Diabetes 2010;59:3017-3022.
44.
Nanda S, Savvidou M, Syngelaki A, et al: Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 2011;31:135-141.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.